MX391538B - Proceso de compuesto antifungico. - Google Patents

Proceso de compuesto antifungico.

Info

Publication number
MX391538B
MX391538B MX2018003357A MX2018003357A MX391538B MX 391538 B MX391538 B MX 391538B MX 2018003357 A MX2018003357 A MX 2018003357A MX 2018003357 A MX2018003357 A MX 2018003357A MX 391538 B MX391538 B MX 391538B
Authority
MX
Mexico
Prior art keywords
antifungal compound
compound process
preparing
useful
compound
Prior art date
Application number
MX2018003357A
Other languages
English (en)
Spanish (es)
Other versions
MX2018003357A (es
Inventor
Christopher M Yates
David Dale Wirth
Eduard Hartmann
Martin F Bindl
William J Hoekstra
Original Assignee
Mycovia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mycovia Pharmaceuticals Inc filed Critical Mycovia Pharmaceuticals Inc
Publication of MX2018003357A publication Critical patent/MX2018003357A/es
Publication of MX391538B publication Critical patent/MX391538B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/713—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with four or more nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235—Nitrogen containing compounds
    • B01J31/0244—Nitrogen containing compounds with nitrogen contained as ring member in aromatic compounds or moieties, e.g. pyridine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C07B63/02—Purification; Separation; Stabilisation; Use of additives by treatment giving rise to a chemical modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/30—Addition reactions at carbon centres, i.e. to either C-C or C-X multiple bonds
    • B01J2231/34—Other additions, e.g. Monsanto-type carbonylations, addition to 1,2-C=X or 1,2-C-X triplebonds, additions to 1,4-C=C-C=X or 1,4-C=-C-X triple bonds with X, e.g. O, S, NH/N
    • B01J2231/341—1,2-additions, e.g. aldol or Knoevenagel condensations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Materials Engineering (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2018003357A 2015-09-18 2016-09-16 Proceso de compuesto antifungico. MX391538B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562220384P 2015-09-18 2015-09-18
US201662275504P 2016-01-06 2016-01-06
PCT/US2016/052128 WO2017049080A1 (en) 2015-09-18 2016-09-16 Antifungal compound process

Publications (2)

Publication Number Publication Date
MX2018003357A MX2018003357A (es) 2018-08-16
MX391538B true MX391538B (es) 2025-03-21

Family

ID=58289604

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018003357A MX391538B (es) 2015-09-18 2016-09-16 Proceso de compuesto antifungico.
MX2018003280A MX391539B (es) 2015-09-18 2016-09-16 Proceso de compuesto antifungico.
MX2018003284A MX2018003284A (es) 2015-09-18 2016-09-16 Compuestos antifungicos y procesos para hacerlos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2018003280A MX391539B (es) 2015-09-18 2016-09-16 Proceso de compuesto antifungico.
MX2018003284A MX2018003284A (es) 2015-09-18 2016-09-16 Compuestos antifungicos y procesos para hacerlos.

Country Status (17)

Country Link
US (4) US10464921B2 (enExample)
EP (3) EP3349753A4 (enExample)
JP (4) JP6887993B2 (enExample)
KR (3) KR102798709B1 (enExample)
CN (3) CN108289457B (enExample)
AU (3) AU2016324148B2 (enExample)
BR (2) BR112018005194B1 (enExample)
CA (3) CA2998808A1 (enExample)
EA (3) EA038214B1 (enExample)
ES (2) ES2821021T3 (enExample)
HK (3) HK1258863A1 (enExample)
HU (1) HUE053638T2 (enExample)
MX (3) MX391538B (enExample)
PL (1) PL3349586T3 (enExample)
TW (3) TWI766842B (enExample)
WO (3) WO2017049096A1 (enExample)
ZA (1) ZA201801404B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017509646A (ja) 2014-03-19 2017-04-06 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
JP2017507991A (ja) 2014-03-19 2017-03-23 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
US10017494B2 (en) 2014-03-19 2018-07-10 Mycovia Pharmaceuticals, Inc. Antifungal compound process
CN109678791B (zh) 2014-03-19 2022-07-01 美国陶氏益农公司 1-(2,4-二氟苯)-2,2-二氟-2-(5-取代吡啶-2-基)乙酮及制备方法
US10196375B2 (en) 2014-03-19 2019-02-05 Mycovia Pharmaceuticals, Inc. Antifungal compound process
CA2942968C (en) 2014-03-19 2022-03-15 William J. Hoekstra Antifungal compound process
WO2015143154A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
JP6572234B2 (ja) 2014-03-19 2019-09-04 ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド 抗真菌化合物の調製方法
US9914726B2 (en) 2014-03-19 2018-03-13 Vps-3, Inc. 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1H-tetrazol-1-yl)propan-2-ols and processes for their preparation
BR112018005194B1 (pt) 2015-09-18 2022-11-08 Vps-3, Inc Processo para preparar um composto antifúngico
CN109666019B (zh) * 2017-10-14 2021-04-06 朱允涛 一种氘代的氮唑醇类化合物及其制备方法和用途
WO2019092086A1 (en) 2017-11-13 2019-05-16 Bayer Aktiengesellschaft Tetrazolylpropyl derivatives and their use as fungicides
WO2021188404A1 (en) * 2020-03-19 2021-09-23 Assia Chemical Industries Ltd Solid state forms of oteseconazole and process for preparation thereof
CN115448848A (zh) * 2021-06-09 2022-12-09 苏州盛迪亚生物医药有限公司 一种抗真菌化合物制备方法
US20240398773A1 (en) * 2021-07-22 2024-12-05 Mycovia Pharmaceuticals, Inc. Compositions comprising oteseconazole
CN114573503B (zh) * 2022-03-28 2024-04-09 浙江天宇药业股份有限公司 一种制备奥特康唑中间体的方法
CN114573557B (zh) * 2022-03-28 2024-03-08 浙江天宇药业股份有限公司 一种奥特康唑的制备方法
CN116621816B (zh) * 2022-09-23 2025-07-04 北京莱瑞森医药科技有限公司 一种伏立康唑对映异构对b的拆分方法
WO2024067784A1 (zh) * 2022-09-30 2024-04-04 上海济煜医药科技有限公司 双环类化合物的无定形、结晶固体及其制备方法
CN119798219B (zh) * 2025-01-13 2025-07-18 长治医学院 一种奥特康唑的制备方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854015B2 (de) 1978-12-14 1980-10-09 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur Herstellung von !H-TetrazoI-1-essigsauren und bestimmter Ester derselben
EP0069442B1 (en) 1981-06-06 1985-02-20 Pfizer Limited Antifungal agents, processes for their preparation, and pharmaceutical compositions containing them
CS228931B2 (cs) 1981-06-06 1984-05-14 Pfizer Způsob výroby 2-(2,4-difluorfenyl)-l,3-bis(lH-l,2,4-triazol-l-yl)propan- -2-oiu
GB8304282D0 (en) 1983-02-16 1983-03-23 Pfizer Ltd Antifungal agents
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
CA2031376A1 (en) 1989-12-04 1991-06-05 Bahram Farhadieh Single layer transdermal drug administration system
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
CA2123809A1 (en) 1991-12-18 1993-06-24 Debra L. Wilfong Multilayered barrier structures
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
JP2000344744A (ja) 1999-06-04 2000-12-12 Ss Pharmaceut Co Ltd アセトフェノン誘導体およびその製法
KR20040050906A (ko) * 2001-10-08 2004-06-17 코닌클리케 필립스 일렉트로닉스 엔.브이. 모션 추정을 위한 장치 및 방법
JP2004359646A (ja) 2003-06-09 2004-12-24 Ss Pharmaceut Co Ltd 抗真菌活性を有する新規アゾール誘導体
US7241800B2 (en) * 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
KR100889937B1 (ko) 2007-08-06 2009-03-20 한미약품 주식회사 보리코나졸의 제조방법
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
KR101109215B1 (ko) 2009-06-17 2012-01-30 보령제약 주식회사 보리코나졸의 신규 중간체 및 이를 이용한 보리코나졸의 제조방법
WO2010146113A1 (en) 2009-06-18 2010-12-23 Basf Se Antifungal 1, 2, 4-triazolyl derivatives having a 5- sulfur substituent
SI2563771T1 (sl) 2010-04-24 2016-05-31 Viamet Pharmaceuticals, Inc. Spojine inhibitorjev metaloencimov
KR20140040235A (ko) 2011-06-19 2014-04-02 비아멧 파마슈티컬즈, 인코포레이티드 금속효소 억제제 화합물
WO2012177635A1 (en) 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
JP2014523880A (ja) 2011-06-23 2014-09-18 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素化合物
TW201329025A (zh) 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
RS57248B1 (sr) * 2011-12-11 2018-07-31 Viamet Pharmaceuticals Nc Inc Jedinjenja inhibitori metaloenzima
IN2014DN06812A (enExample) 2012-01-20 2015-05-22 Viamet Pharmaceuticals Inc
IN2014DN06792A (enExample) 2012-01-20 2015-05-22 Viamet Pharmaceuticals Inc
MA37711A1 (fr) * 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
KR20140012226A (ko) * 2012-07-18 2014-02-03 엘지전자 주식회사 태양전지 모듈
EP2894981B1 (en) 2012-09-12 2019-12-04 Dow AgroSciences LLC Metalloenzyme inhibitor compounds
AU2014209107B2 (en) 2013-01-28 2018-04-12 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
WO2014165861A1 (en) 2013-04-05 2014-10-09 The Regents Of The University Of California Metal-catalyzed coupling of aryl and vinyl halides with alpha, alpha-difluorocarbonyl compounds
US9447073B2 (en) 2013-05-28 2016-09-20 Viamet Pharmaceuticals, Inc. Fungicidal compositions
EP3008051A4 (en) 2013-06-12 2017-03-01 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CA2942968C (en) * 2014-03-19 2022-03-15 William J. Hoekstra Antifungal compound process
US9914726B2 (en) 2014-03-19 2018-03-13 Vps-3, Inc. 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1H-tetrazol-1-yl)propan-2-ols and processes for their preparation
JP6572234B2 (ja) 2014-03-19 2019-09-04 ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド 抗真菌化合物の調製方法
US10017494B2 (en) 2014-03-19 2018-07-10 Mycovia Pharmaceuticals, Inc. Antifungal compound process
CN109678791B (zh) 2014-03-19 2022-07-01 美国陶氏益农公司 1-(2,4-二氟苯)-2,2-二氟-2-(5-取代吡啶-2-基)乙酮及制备方法
AU2015231270B2 (en) 2014-03-19 2019-03-07 Viamet Pharmaceuticals (NC), Inc. Antifungal compound process
JP2017507991A (ja) 2014-03-19 2017-03-23 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
JP2017509646A (ja) 2014-03-19 2017-04-06 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
US10196375B2 (en) 2014-03-19 2019-02-05 Mycovia Pharmaceuticals, Inc. Antifungal compound process
WO2015143154A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
CN107428724B (zh) * 2015-03-19 2021-07-02 迈科维亚医药公司 抗真菌化合物及制备方法
CA2986041C (en) 2015-05-18 2021-06-29 Viamet Pharmaceuticals, Inc. 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(5-thioxo-4,5-dihydro-1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile compounds as antifungal agents
BR112018005194B1 (pt) 2015-09-18 2022-11-08 Vps-3, Inc Processo para preparar um composto antifúngico
CN108473463A (zh) 2015-11-17 2018-08-31 美国陶氏益农公司 4-((6-(2-(2,4-二氟苯基)-1,1-二氟-2-羟基-3-(1h-1,2,4-三唑-1-基)丙基)吡啶-3-基)氧基)苄腈以及制备方法
BR112018009931A8 (pt) 2015-11-17 2019-02-26 Dow Agrosciences Llc 4-((6-(2-(2,4-difluorfenil)-1,1-diflúor-2-hidróxi-3-(1h-1,2,4-triazol-1-il)propil)piridin-3-il)óxi)benzonitrila e processos de preparação
AR106731A1 (es) 2015-11-17 2018-02-14 Viamet Pharmaceuticals Inc 4-((6-(2-(2,4-difluorofenil)-1,1-difluoro-2-hidroxi-3-(1h-1,2,4-triazol-1-il)propil)piridin-3-il)oxi)benzonitrilo y proceso para su preparación
AR106729A1 (es) 2015-11-17 2018-02-14 Viamet Pharmaceuticals Inc 4-((6-(2-(2,4-difluorofenil)-1,1-difluoro-2-oxoetil)piridin-3-il)oxi)benzonitrilo y proceso para su preparación
MX376201B (es) 2015-12-30 2025-03-07 Nqp 1598 Ltd Compuestos inhibidores de metaloenzima.

Also Published As

Publication number Publication date
CA2998807A1 (en) 2017-03-23
HK1258863A1 (zh) 2019-11-22
MX2018003357A (es) 2018-08-16
JP6887993B2 (ja) 2021-06-16
JP2018529687A (ja) 2018-10-11
HUE053638T2 (hu) 2021-07-28
US10513505B2 (en) 2019-12-24
CA2998805C (en) 2023-09-26
US20180258068A1 (en) 2018-09-13
AU2016324148A1 (en) 2018-03-15
US10836740B2 (en) 2020-11-17
KR20180053393A (ko) 2018-05-21
TW201718541A (zh) 2017-06-01
EA201890751A1 (ru) 2018-08-31
HK1263287A1 (zh) 2020-03-20
JP2021121606A (ja) 2021-08-26
EP3349753A1 (en) 2018-07-25
ES2858314T3 (es) 2021-09-30
US10464921B2 (en) 2019-11-05
PL3349586T3 (pl) 2021-05-31
CN108289457B (zh) 2021-08-06
AU2016323782A1 (en) 2018-03-22
EA037521B1 (ru) 2021-04-07
JP2018532719A (ja) 2018-11-08
EP3349586A1 (en) 2018-07-25
US20200024252A1 (en) 2020-01-23
EP3349587B1 (en) 2020-07-22
WO2017049196A1 (en) 2017-03-23
MX2018003284A (es) 2018-08-23
BR112018005198A2 (pt) 2018-10-09
WO2017049080A1 (en) 2017-03-23
EP3349587A1 (en) 2018-07-25
EP3349753A4 (en) 2019-01-23
US20190194160A1 (en) 2019-06-27
TWI730986B (zh) 2021-06-21
MX2018003280A (es) 2018-08-16
CN108347949A (zh) 2018-07-31
EP3349586A4 (en) 2019-04-17
TWI766842B (zh) 2022-06-11
HK1257225A1 (en) 2019-10-18
EA036098B1 (ru) 2020-09-28
US10308632B2 (en) 2019-06-04
CN108347949B (zh) 2021-08-13
AU2016323767B2 (en) 2020-10-15
TW201718540A (zh) 2017-06-01
EP3349586B1 (en) 2020-12-02
WO2017049096A1 (en) 2017-03-23
KR102798709B1 (ko) 2025-04-23
AU2016323782B2 (en) 2020-11-26
EA038214B1 (ru) 2021-07-23
US20180265492A1 (en) 2018-09-20
TW201718497A (zh) 2017-06-01
TWI723047B (zh) 2021-04-01
BR112018005194B1 (pt) 2022-11-08
ZA201801404B (en) 2018-12-19
CN108289457A (zh) 2018-07-17
EP3349587A4 (en) 2019-04-24
JP2018527367A (ja) 2018-09-20
EA201890752A1 (ru) 2018-08-31
CA2998805A1 (en) 2017-03-23
KR20180052755A (ko) 2018-05-18
AU2016324148B2 (en) 2020-10-29
ES2821021T3 (es) 2021-04-23
CN108348511A (zh) 2018-07-31
KR20180100297A (ko) 2018-09-10
JP6847458B2 (ja) 2021-03-24
BR112018005194A2 (pt) 2018-10-09
EA201890522A1 (ru) 2018-08-31
AU2016323767A1 (en) 2018-03-15
CA2998808A1 (en) 2017-03-23
HK1258862A1 (zh) 2019-11-22
MX391539B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
MX391539B (es) Proceso de compuesto antifungico.
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
EA201792535A1 (ru) Гетероциклические амиды в качестве ингибиторов киназ
MX2016012056A (es) Procedimiento de compuesto antifungico.
PH12019550235A1 (en) Kinase inhibitors and uses thereof
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
EA201692219A1 (ru) Способы получения противовирусных соединений
CR20180563A (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que lo contienen
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201691913A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
MX369357B (es) Procedimiento de compuesto antifungico.
MX2018012085A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
MX381344B (es) Compuestos antifungicos y procesos para la fabricacion.
UA120058C2 (uk) Пестицидні композиції
MX2017014459A (es) Compuestos de tioeter como inhibidores de la nitrificacion.
EA201692525A1 (ru) Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов
NZ742952A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида
MX2018016290A (es) Agente antidesgaste.
EA201891431A1 (ru) Способы получения замещенного 5,6-дигидро-6- фенилбензо[f]изохинолин-2-амина
EA201591449A1 (ru) Способы получения противораковых композиций